Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A

Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD03 Applied During AFFiRiS 005A

This is a phase Ib follow-up study to evaluate long-term safety and tolerability of immunization with AFFITOPE AD03 applied during AFFiRiS 005A.

Inclusion Criteria:

• Written informed consent signed and dated by the patient and the caregiver.
• Patients having participated in AFFiRiS 005A and received ≥1 vaccination with AFFITOPE AD03
• Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits and being available for the telephone phone calls

Exclusion Criteria:

• Patients having received no vaccination with AFFITOPE AD03
• History of questionable compliance to visit schedule; patients not expected to complete the clinical trial